A Multicentre Randomized, Double-blind (Sponsor Open), Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs GSK 2831781 (Primary) ; GSK 2831781 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Sponsors GlaxoSmithKline
- 28 Oct 2019 Planned End Date changed from 11 Apr 2022 to 17 Mar 2023.
- 20 May 2019 Status changed from not yet recruiting to recruiting.
- 06 May 2019 Planned initiation date changed from 3 Apr 2019 to 6 May 2019.